title: [Comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats].
abstract: Antiviral activity of the acyclic nucleoside phosphonates 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) against feline immunodeficiency virus (FIV) was investigated in field cats. The study was designed as a placebo-controlled double-blind study enrolling 27 FIV infected cats. Nine cats received PMEA at a dosage of 10 mg/kg body weight, nine cats received FPMPA at a dosage of 25 mg/kg body weight. A variety of parameters were established to evaluate the therapeutic efficacy of the compounds. The improvement was monitored by different aspects: clinical status, index of Karnofsky modified for the cat, laboratory parameters, immunological parameters, surrogate markers, and a virological parameter. Concerning the clinical and immunological parameters cats of both treatment groups disclosed a relevant improvement. Efficacy of antiviral treatment was a little bit higher in the cats treated with PMEA than in the animals injected with FPMPA. However, side effects were also more prominent in the PMEA treated group.
authors.affiliation: I. Medizinischen Tierklinik, Ludwig-Maximilians-Universität München.
authors.forename: M
authors.initials: M
authors.lastname: Kuffer
authors.forename: J
authors.initials: J
authors.lastname: Balzarini
authors.forename: B
authors.initials: B
authors.lastname: Rolinski
authors.forename: F
authors.initials: F
authors.lastname: Goebel
authors.forename: V
authors.initials: V
authors.lastname: Erfle
authors.forename: M
authors.initials: M
authors.lastname: Goldberg
authors.forename: K
authors.initials: K
authors.lastname: Hartmann
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002415:Cats; D004311:Double-Blind Method; D016181:Feline Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D010919:Placebos; C069328:9-(3-fluoro-2-phosphonylmethoxypropyl)adenine; C053001:adefovir; D000225:Adenine
vernacular_title: Vergleichende Untersuchung über die Wirksamkeit zweier Nukleosidanaloga bei FIV-infizierten Katzen.